Holen Sie sich die Stockscreener-App
3.15
7.89%
-0.27
Handel nachbörslich:
3.15
Schlusskurs vom Vortag:
$3.42
Offen:
$3.15
24-Stunden-Volumen:
224.24K
Relative Volume:
1.66
Marktkapitalisierung:
$175.18M
Einnahmen:
$34.16M
Nettoeinkommen (Verlust:
$-98.43M
KGV:
-1.3462
EPS:
-2.34
Netto-Cashflow:
$-119.33M
1W Leistung:
-18.81%
1M Leistung:
-27.08%
6M Leistung:
-57.89%
1J Leistung:
-56.31%
1-Tages-Spanne:
$2.9448
$3.25
1-Wochen-Bereich:
$2.9448
$3.87
52-Wochen-Spanne:
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Vergleichen Sie FHTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
3.15 | 175.18M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients (NASDAQ:FHTX) - Seeking Alpha
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - The AM Reporter
Foghorn Therapeutics Announces New Preclinical Data for - GlobeNewswire
Breakthrough Cancer Drug FHD-909 Reveals Powerful Combination Potential Against Lung Cancer - Stock Titan
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World
2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc. - Defense World
Foghorn Therapeutics adjusts ATM offering to $100M By Investing.com - Investing.com Australia
Foghorn Therapeutics adjusts ATM offering to $100M - Investing.com
What is B. Riley’s Forecast for FHTX Q1 Earnings? - Defense World
Foghorn Therapeutics Reports Progress and Financial Stability - TipRanks
Rhumbline Advisers Purchases 3,049 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics’ (FHTX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy - TipRanks
Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances - TipRanks
Foghorn Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late - Marketscreener.com
Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook - Nasdaq
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - GlobeNewswire
Can Foghorn's $243M War Chest Transform Cancer Treatment? Key Pipeline Updates - StockTitan
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo Canada Finance
Foghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on Thursday - Defense World
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Can Foghorn's Gene Traffic Control Platform Impress Investors at Upcoming Healthcare Conferences? - StockTitan
How To Trade (FHTX) - Stock Traders Daily
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 29% But Growth Is Lacking - Simply Wall St
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health – Company Announcement - Financial Times
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
FHTX Stock Price and Chart — NASDAQ:FHTX - TradingView
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock? - MSN
Layoff Tracker: Q32, Inventiva, Third Harmonic Cut Staff - BioSpace
Eagle financial services executive buys $3,200 in stock - MSN
CENX’s Stock Woes: Up 59.32% in 6 Months, Up 59.32% in Just 5 Days - The InvestChronicle
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Harmony Gold Mining Co Ltd ADR (HMY) Stock: A Study of the Market Performance - The News Heater
Foghorn Therapeutics Inc (FHTX) Shares Up Despite Recent Market Volatility - The News Heater
Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks - Markets Insider
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Yahoo Finance
What is B. Riley's Forecast for FHTX FY2024 Earnings? - MarketBeat
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference - Yahoo Finance
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry - Yahoo Finance
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Upgraded by B. Riley - MarketBeat
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):